Work

Bedside to benchtop translational development: Targeting the S1P/ceramide axis may alleviate symptoms of chemical induced peripheral neuropathy.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e15045

Authors: Ray Takigiku, Robert Wesolowski, Olivier Rixe, John Charles Morris, Emrullah Yilmaz, John L. Villano, Carolyn Muller, Richard Charles Curry, Vinay K. Puduvalli, Trisha Michel Wise-Draper, Darren Wolfe, Gilles Tapolsky

Institutions: Bexion Pharmaceuticals (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Cincinnati, Montefiore Medical Center, University of Kentucky, University of New Mexico, The Ohio State University Wexner Medical Center, The Ohio State University

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281858137

Cites:

Cited by:

Related to: 10